Market Overview

Pandion Therapeutics Announces Appointment of Nancy Stagliano to Its Board of Directors


Therapeutics, Inc.
, a biotechnology company developing novel
therapeutics to treat autoimmune and inflammatory diseases and
transplant rejection, today announced that Nancy Stagliano, PhD will be
joining its board of directors as independent director. She has more
than 20 years of experience in the industry building multiple successful
biotechnology companies. Dr. Stagliano most recently served as the CEO
of True North Therapeutics, where she led the company to its acquisition
by Bioverativ, Inc. for $400M upfront and total potential value of up to
$825M. Previously, she served as CEO of iPierian, which she led to a
successful exit with Bristol-Myers Squibb with $175M upfront and
potential total consideration of $725M. Prior to iPierian, Dr. Stagliano
served as CEO and co-founder of CytomX Therapeutics. "Dr. Stagliano's
extensive experience and valuable insights will be critical as we make
important decisions regarding the growth and direction of the company,"
said Anthony J. Coyle, PhD, co-founder and CEO of Pandion Therapeutics.

Dr. Stagliano joins Dr. Coyle, Alan Crane, co-founder and Chairman of
Pandion, of Polaris Partners, Carlo Rizzuto, PhD, of Versant Ventures,
Mitchell Mutz, PhD, of Roche Venture Fund, and Vikas Goyal of SR One on
Pandion's board of directors. "We look forward to welcoming a true
industry veteran to our board," said Crane.

About Pandion Therapeutics

 is a biotechnology company developing a pipeline of
antibody therapeutics to achieve localized immunomodulation for
autoimmune and inflammatory diseases and transplantation. The company's
proprietary technology platform enables the design of bispecific
antibodies with targeting fragments that bind to specific tissues at the
local site of inflammatory disease, coupled with effector molecules that
modulate immune activity to restore immune homeostasis.

Pandion was founded in 2017 and closed a $58M Series A financing round
in early 2018 with funding from a strong syndicate of investors. The
company is headquartered in Cambridge, Massachusetts. Please visit

View Comments and Join the Discussion!